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Emerging infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) isolates are more
likely to be associated with treatment failures than infections caused by other types of S. aureus. We present
a case of pacemaker lead infective endocarditis caused by a non-daptomycin-susceptible strain of VISA. After
8 weeks of parenteral telavancin therapy, the patient achieved microbiological and clinical cure.
This case involves a 57-year-old woman with rheumatoid
arthritis, paroxysmal atrial fibrillation, asthma, and congenital
complete atrioventricular heart block which had required a
pacemaker for the previous 20 years. She presented to an
outside hospital with a 2-week history of fevers, chills, and
tachycardia. On physical exam, she was found to have small red
macular lesions in her toes and fingers. She was transferred to
our hospital because blood cultures were persistently positive
for methicillin-resistant Staphylococcus aureus (MRSA) with
an elevated MIC of vancomycin of 2 g/ml by the broth mi-
crodilution method. Intravenous vancomycin was replaced
with daptomycin at 8 mg/kg intravenously (i.v.) daily. She re-
mained bacteremic for the next 5 days. A transesophageal
echocardiogram (TEE) revealed multiple small, highly mobile,
linear echogenic densities attached to the pacemaker leads in
the right atrium, consistent with small vegetations. The first S.
aureus isolate cultured from the blood at our hospital was
resistant to cefazolin, clindamycin, erythromycin, oxacillin, and
penicillin by the disk diffusion method and susceptible to doxy-
cycline, linezolid, trimethoprim-sulfamethoxazole, and vanco-
mycin. By broth microdilution, MICs for this S. aureus isolate
were 2 g/ml of vancomycin, 0.5 g/ml of daptomycin, and 4
g/ml of linezolid. On day 6 of hospitalization, the pacemaker
was explanted and replaced with a temporary transvenous
pacemaker because of her complete heart block. MRSA was
also isolated from the pacemaker pocket. On day 10, blood
cultures became sterile for the first time since the patient had
been on intravenous daptomycin at 8 mg/kg i.v. daily. On day
15, however, the patient developed ventricular tachycardia,
and blood cultures were again positive for MRSA. At this
point, daptomycin was increased to 10 mg/kg i.v. daily. On day
17, because of back pain and the recurrence of bacteremia, a
computed tomography of the chest, abdomen, and pelvis was
performed to search for other potential sources of bacteremia.
The exam revealed a large epidural abscess at the level of the
L4-L5 spine and two retained foreign bodies (part of the pace-
maker wire, approximately 1 cm and 2 cm in length) lodged in
her pulmonary arteries. On day 18, the MICs for the MRSA
isolate from the blood sample drawn on hospital day 15 were
available, and they were 4 g/ml of vancomycin (VISA) and 2.0
g/ml of daptomycin (non-daptomycin-susceptible S. aureus
[DNSSA]); the linezolid MIC remained at 4 g/ml by the broth
microdilution method and the telavancin MIC was 0.25 g/ml
by Etest. Daptomycin was discontinued and telavancin was
initiated at 10 mg/kg i.v. daily. On day 19, blood cultures were
negative, and the patient underwent incision and drainage and
laminectomy of the L4-L5 vertebrae. Gram stain of the oper-
ating room cultures was positive for Gram-positive cocci in
clusters, but cultures were sterile. The blood samples drawn on
the same day were sterile again, and all blood samples drawn
afterwards remained sterile. A repeat TEE on day 24 (day 6 of
telavancin) showed new multiple smaller echogenic densities
consistent with vegetations along the superior cava vein and on
the temporary wire. On day 33, at 15 days after initiation of
telavancin, since all blood samples drawn after day 19 re-
mained sterile, new epicardial ventricular leads were im-
planted and the temporary, presumably infected, pacemaker
wire was removed. The patient continued to improve clinically
and completed an 8-week course of telavancin at a skilled
nursing care/rehabilitation facility. Her renal function (creati-
nine level) was monitored at least twice a week, and it re-
mained normal throughout the course of therapy. Because of
the potentially infected piece of pacemaker wire lodged in the
pulmonary artery, she was treated with doxycycline at 100
mg orally twice a day as chronic suppressive therapy. At
follow-up 2 months after completion of therapy, she com-
plained only of chronic back pain and was able to walk short
distances again. Surveillance blood samples drawn after dis-
continuation of telavancin and 2 weeks prior to the fol-
low-up were sterile. A summary of the clinical course and
MICs is presented in Table 1.
The emergence of vancomycin-intermediate S. aureus (VISA)
and heterogeneous vancomycin-intermediate S. aureus (hVISA)
subpopulations of MRSA and VISA has been associated with a
high rate of glycopeptide treatment failures (5). Infections caused
by these isolates, which are tolerant of vancomycin, are particu-
larly difficult to treat because of limited data on the alternatives to
vancomycin. This is also complicated by reports that VISA strains
which initially test susceptible to daptomycin have been found to
develop higher MICs of daptomycin during therapy and become
nonsusceptible, as in this case. This phenomenon is thought to be
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secondary to changes in the cell wall caused by a single point
mutation at position 1259 in the mprF gene that impacts cell
membrane biosynthesis (6).
Currently, vancomycin is the therapy for MRSA endocardi-
tis recommended by the American Heart Association guide-
lines for treatment of infective endocarditis (IE) (1). Very
limited data are available on IE caused by VISA. Linezolid has
been reported to be successful at treating cases of MRSA
endocarditis, but therapy with linezolid can be limited because
of its nonbactericidal effect on MRSA and its potential long-
term adverse effects and drug-drug interactions. Daptomycin
has been shown to be effective for MSSA and MRSA bacte-
remia, including right-sided endocarditis, and well tolerated
(3), but nonsusceptible isolates of MRSA and VISA are being
reported. IE is difficult to treat because it involves a large
amount of organisms and valvular vegetations are not easily
penetrated by antibiotics, especially glycopeptides, to exert
their effect. The hVISA phenotype is also more likely to be
expressed in the presence of subtherapeutic drug levels, which
makes infection of the heart valves an ideal site for expression
of heterogeneous resistance (4). In a recent study that evalu-
ated hVISA and MRSA phenotypes in IE, the hVISA pheno-
type was present in five isolates (83%; n  6) reported to have
a vancomycin MIC of 2 g/ml as determined by the Etest
method and in eight isolates (62%; n  13) as determined by
broth microdilution (2). Although we do not have the capabil-
ity to test heterogeneous resistance to vancomycin, the MRSA
and VISA isolates/colonies in our case are consistent with the
hVISA phenotype, since all initial blood cultures showed
MRSA with a vancomycin MIC of 2 g/ml. But later on, after
being exposed to both vancomycin and daptomycin, colonies
with higher MICs of vancomycin and daptomycin were iso-
lated. An uncontrolled source of infection such as endocarditis
may increase the emergence of subpopulations with variable
resistance to glycopeptides. Without the use of glycopeptides
like vancomycin, therapeutic options for MRSA endocarditis
are limited, and clinicians may have to use antimicrobials for
which there is very limited clinical experience to date.
Telavancin, a semisynthetic derivative of vancomycin, is a
novel lipoglycopeptide with rapid bactericidal activity and two
mechanisms of action against Gram-positive bacteria, includ-
ing methicillin-resistant, glycopeptide-intermediate, and van-
comycin-resistant strains of S. aureus. Its dual mechanism of
action is characterized by inhibition of the transglycosylation
process of peptidoglycan cell wall synthesis by the formation of
a complex with the D-alanyl-D-alanine precursors and depolar-
ization of the bacterial membrane. In addition, its activity
against a contemporary (2007-2008) global collection of 10,000
S. aureus isolates showed that it was very active against MSSA
and MRSA, with MICs for 50% and 90% of isolates of both
types of 0.12 and 0.25 g/ml. It was also two-, four-, and
eightfold more potent against MRSA than daptomycin, van-
comycin, and quinupristin-dalfopristin and linezolid, respec-
tively (8).
The clinical experience with telavancin for treatment of
MRSA IE is limited to just one case report. To our knowledge,
this is the first case report of VISA endocarditis treated with
telavancin. There are two experimental rabbit models of aortic
valve endocarditis caused by VISA and MRSA, and those
studies showed that telavancin rapidly sterilizes the vegetations
but at serum levels that are 5 to 10 times higher than serum
levels achieved in human studies (7, 9). There is only one
published case report of MRSA IE (vancomycin MIC  0.5
g/dl) that was treated successfully with telavancin (10). The
authors reported that the patient was treated with telavancin
after he continued to have persistent bacteremia, but persistent
bacteremia from MRSA endocarditis is not an uncommon
occurrence. In our case, the isolate was both a VISA and a
DNSSA and also had a high MIC of linezolid (4 g/ml). Tela-
vancin was chosen over linezolid because of its bactericidal
activity, as opposed to the bacteriostatic activity of linezolid,
and to avoid serotonin syndrome, since our patient was on a
selective serotonin reuptake inhibitor (SSRI). In this case, the
bacteremia resolved within 48 h of the initiation of telavancin.
Although clearance of bacteremia could have been attributed
to the administration of high-dose daptomycin, telavancin was
used to complete the patient’s treatment for endocarditis, os-
teomyelitis, and epidural abscess in the presence of a non-
daptomycin-susceptible VISA isolate. This case indicates that
the presence of VISA isolates can be induced by treatment
with glycopeptides and lead to therapeutic failure. We recom-
mend repeat resistance testing of isolates that are cultured
from deep-seated infections during glycopeptide therapy, since
these isolates may be susceptible to vancomycin and daptomy-
cin at initiation of therapy but then become intermediately
susceptible or even nonsusceptible after prolonged exposure to
the antimicrobials. Nonetheless, the most important therapeu-
tic intervention in this case was likely the controlling of the
source of the infection (epidural abscess). Only through vigi-
lance were we able to provide adequate therapy for these
deep-seated infections. In conclusion, we report the successful
treatment of a patient with complicated VISA endocarditis
TABLE 1. Summary of days of bacteremia, blood culture results, antibiotics MICs, and therapy
Day Result for bacteremia
MICa (g/ml) of:
Therapy
Vancomycin Daptomycin Televancin Linezolid
1b First blood culture positive at hospital 1 2 NA NA NA Vancomycin, 1 g i.v. q12h
1 First blood culture positive at hospital 2 2 0.5 NA 4 Daptomycin, 6 mg/kg i.v. q24h
10 Last blood culture positive before initial sterilization 2 0.5 NA 4 Daptomycin, 8 mg/kg i.v. q24h
15 First new blood culture positive Daptomycin, 10 mg/kg i.v. q24h
18 4 2.0 0.25 4 Telavancin, 10 mg/kg i.v. q24h
19 Negative blood culture Epidural abscess drainage
a MICs were determined by broth microdilution for vancomycin, daptomycin, and linezolid and by Etest for telavancin. NA, not available.
b One day prior to transfer to hospital 2.
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who had multiple subpopulations of S. aureus, including
MRSA, VISA, and DNSSA. To our knowledge, this is the first
case of VISA endocarditis successfully treated with telavancin.
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